# The Influence of the Amino Acid Transporter LAT1 on Patient Prognosis and the Relationships between Tumor Immunometabolic and Proliferative Features Depend on Menopausal Status in Breast Cancer

Gautham Ramshankar<sup>1,2</sup>, Ryan Liu<sup>2,3</sup>, and Rachel J. Perry<sup>2</sup>\* <sup>1</sup>Irvington High School, Fremont, CA <sup>2</sup>Departments of Cellular & Molecular Physiology and Internal Medicine (Endocrinology), Yale School of Medicine, New Haven, CT <sup>3</sup>Cedar Park High School, Cedar Park, TX \*Correspondence to: rachel.perry@yale.edu

## 14 Abstract

5

6 7

8

9 10

11 12

13

15 L-type Amino Acid Transporter 1 (LAT1) facilitates the uptake of specific essential amino acids, and due to this quality, it has been correlated to worse patient outcomes in various cancer types. 16 However, the relationship between LAT1 and various clinical factors, including menopausal 17 status, in mediating LAT1's prognostic effects remains incompletely understood. This is 18 19 particularly true in the unique subset of tumors that are both obesity-associated and responsive to 20 immunotherapy, including breast cancer. To close this gap, we employed 6 sets of transcriptomic 21 data using the Kaplan-Meier model in the Xena Functional Genomics Explorer, demonstrating 22 that higher LAT1 expression diminishes breast cancer patients' survival probability. Additionally, we analyzed 3'-Deoxy-3'-<sup>18</sup>F-Fluorothymidine positron emission tomography-23 computed tomography (<sup>18</sup>F-FLT PET-CT) images found on The Cancer Imaging Archive 24 (TCIA). After separating all patients based on menopausal status, we correlated the measured 25 26 <sup>18</sup>F-FLT uptake with various clinical parameters quantifying body composition, tumor proliferation, and immune cell infiltration. By analyzing a wealth of deidentified, open-access 27 28 data, the current study investigates the impact of LAT1 expression on breast cancer prognosis, 29 along with the menopausal status-dependent associations between tumor proliferation, immunometabolism, and systemic metabolism. 30 31

# 32 Introduction

33 As the second leading cause of cancer deaths in women, breast cancer has become a major

34 clinical and social burden, with annual out-of-pocket costs for breast cancer care in the U.S.

exceeding \$3 billion in 2019 [1]. Because breast cancer has high economic and social costs, it

- 36 has become increasingly necessary to identify potential risk factors, biomarkers, and treatments.
- 37 Nearly 30% of breast cancer deaths are caused by modifiable risk factors like excess body

weight and alcohol consumption [2]. Several of the modifiable risk factors that predispose to 38 39 breast cancer converge on metabolism. Consequently, a key priority in the cancer field has been to investigate tumor metabolism and how it can be affected by a patient's lifestyle. In the 1920s, 40 41 Otto Warburg discovered that in order to sustain their energetic needs while prioritizing 42 generating the biomass and nucleotides required for rapid proliferation and growth, cancer cells have greater metabolic demands than their benign counterparts. Because of this, oncogenic 43 44 metabolism is characterized by heightened glycolytic metabolism, which necessitates greater 45 uptake of glucose. This phenomenon is now called the Warburg Effect and has greatly shaped the field of tumor metabolism [3]. However, many years after Warburg's groundbreaking work 46 47 identifying glucose metabolism as a key contributor to tumor pathogenesis, there remains relatively less investigation into the role of amino acid metabolism in tumor progression. The 48 same can be said about amino acid metabolic reprogramming, the abnormal changes to amino 49 50 acid uptake or metabolic pathways caused by tumor progression. However, past literature has 51 shown that low concentrations of amino acids in the tumor microenvironment inhibit nearby 52 immune cells, weakening immune responses to tumor cells and contributing to tumor progression [4,5]. These data beg further investigation of the tumor- and/or immune cell-centric 53 54 metabolic role of amino acids in the tumor microenvironment.

55

56 In order to leave the tumor interstitial compartment and undergo metabolism by tumor cells,

57 amino acids must cross the plasma membrane with the help of amino acid transporters. Amino

58 acid transporters can thus facilitate the uptake of amino acids to meet the metabolic needs of

59 cancer cells, explaining why the expression of these transporters has been associated with the

60 proliferation of cancer cells. One such transporter, L-type amino acid transporter 1 (LAT1) is

- 61 particularly important in the amino acid transport process [4]. Encoded by the gene Solute
- 62 Carrier Family 7 Member 5 (*SLC7A5*), LAT1 is a light-chain protein that heterodimerizes with

63 its heavy-chain partner 4F2hc (*SLC3A2*) through a conserved disulfide bridge, forming the

- 64 human LAT1-4F2hc complex. A sodium-independent transporter, LAT1 is an integral membrane
- 65 protein that mediates the transport of large neutral amino acids like methionine, leucine, and

66 histidine by exchanging them with intracellular glutamine [6]. LAT1 is unique in that it

67 transports multiple essential amino acids, which cannot be synthesized by the human body and

68 must be obtained through diet [7,8]. Considering the dietary dependence of its transported

69 molecules, LAT1 is a particularly intriguing target to participate in the links between lifestyle,

- 70 systemic metabolism, and cancer.
- 71

72 Positron emission tomography-computed tomography (PET-CT) is a powerful tool in cancer

73 metabolism research due to its ability to visualize thin slices of tissue in vivo and quantify cells'

74 metabolic activity by measuring radiotracers like 3'-Deoxy-3'-<sup>18</sup>F-Fluorothymidine (<sup>18</sup>F-FLT).

An analog of the nucleoside thymidine,  $^{18}$ F-FLT is phosphorylated by the cytosolic enzyme

76 thymidine kinase 1 (TK1) and taken up into the cell. During the S-phase of the cell cycle, TK1 is

77 overexpressed nearly tenfold and <sup>18</sup>F-FLT uptake is at its highest. In this way, concentrations of

- <sup>18</sup>F-FLT and TK1 are elevated in cancer cells, making <sup>18</sup>F-FLT uptake a quantitative marker for
- tumor proliferation [9–12]. Ki-67 is a nuclear nonhistone protein, and because it is only
- 80 expressed in cells that are not in the  $G_0$  phase of the cell cycle, it can only be observed in
- 81 actively-proliferating cells. This quality has made Ki-67 a classic proliferative marker for tumor
- 82 cells [13], and is included in the datasets analyzed in the current report.
- 83

84 Past studies have demonstrated that menopausal status affects to what extent obesity is a risk

- 85 factor for developing breast cancer. In multiple studies, obesity has been observed to have a
- 86 protective relationship with breast cancer risk in premenopausal patients whereas it is a risk
- 87 factor for breast cancer in postmenopausal patients [14]. Because of this, we segmented our  $\frac{1}{2}$
- analyses based on patients' menopausal statuses. We used body mass index (BMI) in  $kg/m^2$  as a
- metric for obesity. By analyzing PET-CT scans of 58 patients from The National Cancer
   Imaging Archive (TCIA), we correlate patients' calculated <sup>18</sup>F-FLT uptake and Ki-67 index
- Imaging Archive (TCIA), we correlate patients' calculated <sup>18</sup>F-FLT uptake and Ki-67 index
   values to their BMIs to study the relationship between obesity and breast cancer [10,15,16].
- values to their Bivits to study the relationship between obesity and breast cancer [10,13,10]
- 92

93 To demonstrate the relationship between LAT1 and poorer health outcomes with a larger sample

size, we leveraged RNA-seq data in the UCSC Xena Functional Genomics Explorer [17]. This

allowed us to visualize the effect of LAT1 expression on breast cancer prognosis in

- 96 premenopausal and postmenopausal patients. Ultimately, we used a similar workflow to our prior
- 97 published work to examine the impact of SLC7A5, a gene with a drastically different role in
- 98 metabolism, in breast cancer [18]. Our analyses reveal new insights into the associations between
- 99 clinical variables (obesity, menopausal status), cell proliferation, infiltration with multiple
- 100 immune cell subtypes, tumor LAT1 expression, and survival in breast cancer patients, which
- 101 deepen our understanding of the bidirectional relationships that may inform interventional
- 102 studies targeting these variables in individuals with breast cancer.
- 103

# 104 Methods

## 105 <sup>18</sup>F-FLT PET-CT Quantitative Image Analysis

106 Deidentified PET-CT images produced during the ACRIN 6688 clinical trial [10] were obtained

- from The Cancer Imaging Archive (TCIA). This dataset, "ACRIN-FLT-Breast (ACRIN 6688)",
  can be found here:
- 109 <u>https://wiki.cancerimagingarchive.net/pages/viewpage.action?pageId=30671268</u>. Because only
- 110 publicly available, deidentified data were analyzed, separate ethical approval is not required. We
- analyzed the scans of all patients with a menopausal status, height, weight, and 5 clear CT slices
- 112 (i.e., slices in which the primary breast tumor could be identified and its corresponding SUV
- values could be generated) present in the dataset. 58 of the 90 enrolled patients in the ACRIN
- 114 clinical trial met these criteria, and all were analyzed. Of these 58 patients, 26 were
- premenopausal and 32 were postmenopausal. Scans taken at 3 different dates were available for
- 116 most patients, and we used the earliest scan (from the baseline scanning which was defined to be
- 117 4 weeks before any treatment was administered) to minimize the chemotherapeutic effect of the

treatment used in the clinical trial. Likewise, heights and weights measured on patients' first

119 visits were used. These data were selected for analysis because breast cancer treatment often

120 causes some weight gain [19–22], which may obscure differences in BMI that could promote

- 121 proliferation.
- 122

123 The patients' images were uploaded to Fiji ImageJ and we used the PET-CT Viewer plugin to

- 124 view and analyze them. After identifying the primary breast tumor on the PET image, we
- selected the tumor and used the Brown Fat Volume tool to draw fixed-volume spheres around
- 126 the interior regions of interest (ROIs) on the CT slice. 5 slices were used from each patient's
- scan. SUV parameters were set at 2 to 15, and <sup>18</sup>F-FLT uptake was calculated in the tumor tissue
   in the specified ROI. <sup>18</sup>F-FLT uptake on PET-CT scans is measured by calculating and recording
- in the specified ROI. <sup>18</sup>F-FLT uptake on PET-CT scans is measured by calculating and record
   lean body mass-corrected standardized uptake values (SUV) of which there are 3 types:
- 130  $SUV_{Mean}$ ,  $SUV_{Max}$ , and  $SUV_{Peak}$ . After positioning a fixed-volume sphere on a tumor, within the
- 131 ROI, SUV<sub>Mean</sub> represents the average SUV, SUV<sub>Max</sub> indicates the maximum SUV, and SUV<sub>Peak</sub>
- 132 corresponds to the SUV derived from a localized cluster of voxels with high uptake [10,23]. The
- primary endpoint of image analysis was BMI  $(kg/m^2)$  correlated to the 3 types of tumor SUV
- 134 (g/mL).
- 135

## 136 LAT1 Prognostic Analysis

- Using the UCSC Xena Functional Genomics Browser (<u>https://xenabrowser.net/</u>), we accessed the
  "TCGA Breast Cancer (BRCA) cohort" (found here:
- 139 <u>https://xenabrowser.net/datapages/?cohort=TCGA%20Breast%20Cancer%20(BRCA)&removeH</u>
- 140 <u>ub=http%3A%2F%2F127.0.0.1%3A7222</u>) which included 2 datasets. The BRCA cohort had
- 141 1247 total patients, and all of them had menopausal statuses recorded, which we accessed
- 142 through the "Phenotypes" dataset:
- $\label{eq:https://xenabrowser.net/datapages/?dataset=TCGA.BRCA.sampleMap & 2FBRCA\_clinicalMatrientering and the set of the set of$
- $\label{eq:linear_state} 144 \qquad \underline{x\&host=https\%3A\%2F\%2Ftcga.xenahubs.net\&removeHub=https\%3A\%2F\%2Fxena.treehouse.}$
- 145 <u>gi.ucsc.edu%3A443</u>. 1236 of the 1247 patients had survival data recorded. The "IlluminaHiSeq"
- 146 dataset was used to study LAT1 expression and it can be found here:
- 147 <u>https://xenabrowser.net/datapages/?dataset=TCGA.BRCA.sampleMap%2FHiSeqV2&host=https</u>
- 148  $\frac{\%3A\%2F\%2Ftcga.xenahubs.net&removeHub=http\%3A\%2F\%2F127.0.0.1\%3A7222}{\%3A\%2F\%2F127.0.0.1\%3A7222}$
- 149 "IlluminaHiSeq" dataset used fragments per kilobase of exon per million mapped fragments
- 150 (FPKM) to measure gene expression. Again, only openly available human data were analyzed.
- 151 1218 of the 1247 patients had LAT1 expression data. These datasets were used alongside the
- 152 Kaplan-Meier model in the Xena visualization suite to analyze LAT1 and its effect on breast
- 153 cancer prognosis.
- 154
- 155 To analyze LAT1 expression, the following workflow was used: the 1247 patients were added to
- 156 Column A. SLC7A5 was added to Column B as a genomic variable with the gene expression
- 157 dataset selected, and menopause status was added to Column C as a phenotypic variable. After

removing null and duplicate samples, a Kaplan-Meier (KM) plot was generated in Column B to

- show LAT1 expression and its effect on prognosis in 1005 of the 1247 patients. Next, low and
- 160 high-expression groups were created from these patients. After 34 patients with indeterminate
- 161 menopausal statuses were removed from the dataset, 10.46 FPKM was calculated by Xena to be
- the median for LAT1 expression. Patients were divided at the median: 485 patients were in the
- 163 low expression group (< 10.46 FPKM), and 486 patients were in the high expression group (>=
- 164 10.46 FPKM). A KM plot was generated for each group using Column C, creating 2 KM plots
- 165 with the premenopausal, perimenopausal, and postmenopausal patients in each expression group.
- 166
- 167 In addition to the BRCA dataset, the following datasets were used to access breast cancer
- 168 patients' gene expression data: "RSEM norm-count" from the "TCGA TARGET GTEx" cohort
- 169 (https://xenabrowser.net/datapages/?dataset=TcgaTargetGtex\_RSEM\_Hugo\_norm\_count&host=
- 170 <u>https%3A%2F%2Ftoil.xenahubs.net&removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.ed</u>
- 171 <u>u%3A443</u>), "Desmedt 76 Gene Node-Neg Gene Exp" from the "node-negative breast cancer
- 172 (Desmedt 2007)" cohort
- 173 (https://xenabrowser.net/datapages/?dataset=desmedt2007\_public%2Fdesmedt2007\_genomicMa
- 174 <u>trix&host=https%3A%2F%2Fucscpublic.xenahubs.net&removeHub=https%3A%2F%2Fxena.tre</u>
- 175 <u>ehouse.gi.ucsc.edu%3A443</u>), "gene expression RNAseq US projects" from the "ICGC (donor
- 176 centric)" cohort
- 177 (https://xenabrowser.net/datapages/?dataset=donor%2Fexp\_seq.all\_projects.donor.USonly.xena.t
- $178 \qquad \underline{sv\&host=https\%3A\%2F\%2Ficgc.xenahubs.net\&removeHub=https\%3A\%2F\%2Fxena.treehouse.}$
- 179 <u>gi.ucsc.edu%3A443</u>), "Gene Expression" from the "Breast Cancer (Chin 2006)" cohort
- 180 (https://xenabrowser.net/datapages/?dataset=chin2006\_public%2Fchin2006Exp\_genomicMatrix
- 181 <u>&host=https%3A%2F%2Fucscpublic.xenahubs.net&removeHub=https%3A%2F%2Fxena.treeh</u>
- 182 <u>ouse.gi.ucsc.edu%3A443</u>), and "Miller TP53 Gene Exp" from the "Breast Cancer (Miller 2005)"
   183 cohort
- 184 (https://xenabrowser.net/datapages/?dataset=miller2005\_public%2Fmiller2005\_genomicMatrix
- 185 &host=https%3A%2F%2Fucscpublic.xenahubs.net&removeHub=https%3A%2F%2Fxena.treeh
- 186 ouse.gi.ucsc.edu%3A443). To measure expression, the "TCGA TARGET GTEx" dataset used
- 187 FPKM, the "ICGC (donor centric)" dataset used normalized read count, and the "Node-negative
- 188 breast cancer (Desmedt 2007)" and "Breast Cancer (Miller 2005)" datasets used log2 units.
- 189 Although these gene expression datasets did not include menopausal status as a possible
- 190 phenotypic variable, our selection criteria were to include breast cancer datasets that had RNA-
- seq data on SLC7A5 and survival data from the same patients that could be used to produce
- 192 Kaplan-Meier plots on the Xena platform. Each dataset was used in the same way: SLC7A5 was
- 193 selected as a genomic variable in Column B, and after null and duplicate samples were removed,
- 194 a KM plot was generated. For the "TCGA TARGET GTEx" and "ICGC (donor centric)"
- 195 datasets, only patients with breast tumors were selected for the analysis.
- 196

197 All of the KM plots were created with Overall Survival as the dependent variable unless

- 198 otherwise specified. After patients were split at the median for the gene expression analyses,
- some groups had an unequal number of patients because patients with the same expression levels
- 200 were put in the same group. Some patients were at the expression median, and the median was
- 201 calculated to ensure they were placed in the high-expression group while keeping the sizes of
- 202 each expression group roughly the same.
- 203

### 204 Statistical Analysis

- 205 Correlation tests were performed between patients' SUV and BMI values. 26 premenopausal
- patients' BMIs ranged from 23.829 to 142.822 kg/m<sup>2</sup> (mean [SD] = 33.972 [22.584]), and 32 postmenopausal patients' BMIs ranged from 17.940 to 199.219 kg/m<sup>2</sup> (mean [SD] = 40.865
- 208 [36.818]). The unusually high BMI values are driven by unusually low heights reported for these
- 209 patients; however, only one premenopausal and postmenopausal patient had a reported BMI
- 210 above 100. Because 5 slices were used per patient, each patient had 5 SUV<sub>Max</sub> values and 5
- 211 SUV<sub>Peak</sub> values but only 1 BMI. In order to correlate BMI and SUV, we needed the same number
- of values for each. In order to get one SUV for each patient, we took the mean of the SUVs
- 213 produced from all 5 slices. For SUV<sub>Mean</sub>, the calculated SUV had a margin of error indicated by a
- plus-minus sign. This meant that the calculation of each SUV<sub>Mean</sub> yielded 2 numerical values,
- 215 one being the high value and the other being the low value, so 5 slices yield 10 SUV<sub>Mean</sub> values
- per patient. We took the mean of these 10 values for each patient. Each of these individual SUVswas then correlated with each patient's BMI.
- 218

We also correlated each patient's 3 types of SUVs to their Ki-67 values to further inform the validity of <sup>18</sup>F-FLT uptake as a metric for tumor proliferation. BMI was also correlated to Ki-67. All correlations were two-tailed Pearson correlation tests performed after patients' data were segmented by menopausal status. Shapiro-Wilk tests were also performed to determine if any groups of data were normally distributed. Student's t-tests and Mann-Whitney U tests were performed on parametric and nonparametric data, respectively, to assess difference. For both tests, all data were transformed using log2 fold changes of the mean.

226

227 Unless otherwise specified, statistical analysis was done and graphs were made in Python 3.9 using the pandas (version 1.5) and SciPy (version 1.10) libraries. The two-tailed Pearson 228 229 correlation tests were conducted using the "pearsonr" function from the scipy.stats module. The Mann-Whitney U tests were conducted using the "mannwhitney" function, the Student's t-tests 230 were conducted using the "ttest ind" function, and the Shapiro-Wilk tests were performed using 231 232 the "shapiro" function, all from the scipy stats module. All Python code can be found here: 233 https://github.com/gramshankar/LAT1BreastCancer. For each of the KM plots, a log-rank test was conducted by Xena to compare the curves in the graph. Test statistics and p-values were 234 235 calculated. Statistical significance was indicated by p-values less than 0.05, and marginally

significant results have p-values greater than 0.05 but less than 0.10.
Results
Correlation analysis between proliferative markers, obesity, and immune cells by
menopausal status
In premenopausal patients, Ki-67 insignificantly positively correlated with $SUV_{Mean}$ , $SUV_{Peak}$ (marginal significance), and $SUV_{Max}$ (marginal significance) (Fig 1A). However, the relationship
between Ki-67 and tumor <sup>18</sup> F-FLT uptake was statistically stronger in postmenopausal patients, in whom Ki-67 significantly positively correlated with $SUV_{Mean}$ , $SUV_{Peak}$ , and $SUV_{Max}$ (Fig 1B).
In premenopausal patients, BMI insignificantly negatively correlated with SUV <sub>Mean</sub> , SUV <sub>Peak</sub> ,
and SUV <sub>Max</sub> (Fig 1A). In postmenopausal patients, BMI insignificantly positively correlated with
$SUV_{Mean}$ (marginal significance), $SUV_{Peak}$ , and $SUV_{Max}$ (Fig 1B). In premenopausal and
postmenopausal patients, BMI insignificantly positively correlated with Ki-67 (Fig 1A, Fig 1B).
In premenopausal patients, basophil, eosinophil, neutrophil, monocyte, and lymphocyte counts
insignificantly negatively correlated with $SUV_{Mean}$ , $SUV_{Peak}$ , and $SUV_{Max}$ . White blood cell
counts insignificantly positively correlated with SUV <sub>Mean</sub> , SUV <sub>Peak</sub> , and SUV <sub>Max</sub> . All immune
cells insignificantly negatively correlated with Ki-67 (Fig 1A).
In postmenopausal patients, basophil, eosinophil, monocyte, white blood cell, and lymphocyte
counts insignificantly positively correlated with $SUV_{Mean}$ , $SUV_{Peak}$ , and $SUV_{Max}$ . Neutrophil
counts insignificantly negatively correlated with SU $v_{\text{Mean}}$ , SU $v_{\text{Peak}}$ , and SU $v_{\text{Max}}$ . Basophil, eosinophil, monocyte, and lymphocyte counts insignificantly negatively correlated with Ki-67
Neutrophil and white blood cell counts insignificantly positively correlated with Ki-67 (Fig 1B)
real opini and white blood cen counts insignificantly positively concluded with Ri or (Fig 1D).
In premenopausal patients, BMI negatively correlated with basophil, eosinophil, monocyte, and
lymphocyte counts and positively correlated with neutrophil and white blood cell counts (Fig
1A). Opposite relationships were observed in postmenopausal patients, in whom BMI positively
correlated with basophil, eosinophil, monocyte, and lymphocyte counts and negatively correlated
with neutrophil and white blood cell counts (Fig 1B).
These correlation tests' p-values are presented in Tables 1 - 4. In addition, the results from the
Mann-Whitney and Student's t-tests performed are presented in Tables 5 - 8.





Fig 1. Correlations between clinical variables. Proliferative markers (Ki-67 and lean body mass-corrected <sup>18</sup>F-FLT uptake measured by SUV<sub>Mean</sub>, SUV<sub>Peak</sub>, and SUV<sub>Max</sub>), obesity (BMI), and immune cell counts (basophil, eosinophil, neutrophil, monocyte, white blood cell, and lymphocyte) were correlated in (A) premenopausal and (B) postmenopausal patients. Pearson r values were calculated and correlation matrices were generated in GraphPad Prism version 9.5.1.

	Premenopausal Patients	Postmenopausal Patients
$\mathrm{SUV}_{\mathrm{Mean}}$	0.114	0.035
$\mathrm{SUV}_{\mathrm{Peak}}$	0.081	0.045
SUV <sub>Max</sub>	0.078	0.029

**Table 1. P-values from correlations between Ki-67 and <sup>18</sup>F-FLT uptake.** Significant results are bolded and marginally significant results are bolded and italicized.

279

280

	Premenopausal Patients	Postmenopausal Patients
$\mathrm{SUV}_{\mathrm{Mean}}$	0.279	0.095
$\mathrm{SUV}_{\mathrm{Peak}}$	0.335	0.342
SUV <sub>Max</sub>	0.268	0.437
Ki-67	0.767	0.691

**Table 2. P-values from correlations between BMI and proliferative markers.** Marginally significant results are bolded and italicized.

281

	Basophils	Eosinophils	Neutrophils	Monocytes	WBC	Lymphocyte
$\mathrm{SUV}_{\mathrm{Mean}}$	0.395	0.539	0.334	0.190	0.170	0.472
SUV <sub>Peak</sub>	0.401	0.620	0.420	0.262	0.326	0.404
$SUV_{Max}$	0.519	0.691	0.520	0.342	0.408	0.537
Ki-67	0.394	0.712	0.626	0.417	0.769	0.132

Table 3. P-values from correlations between immune cells and proliferative markers in premenopausal patients.

282

	Basophils	Eosinophils	Neutrophils	Monocytes	WBC	Lymphocyte
$\mathrm{SUV}_{\mathrm{Mean}}$	0.239	0.237	0.671	0.235	0.927	0.233
SUV <sub>Peak</sub>	0.560	0.563	0.586	0.560	0.913	0.561
$\mathrm{SUV}_{\mathrm{Max}}$	0.682	0.685	0.741	0.679	0.946	0.681
Ki-67	0.781	0.737	0.986	0.723	0.783	0.762

 Table 4. P-values from correlations between immune cells and proliferative markers in postmenopausal patients.

	Premenopausal Patients	Postmenopausal Patients
$\mathrm{SUV}_{\mathrm{Mean}}$	0.959	0.291
SUV <sub>Peak</sub>	0.926	0.528
SUV <sub>Max</sub>	0.992	0.436

Table 5. Mann-Whitney U tests identify no significant differences between the log2 fold change in Ki-67 and <sup>18</sup>F-FLT uptake in pre- or postmenopausal patients. P-values are shown.

284

	Premenopausal Patients		Postmenopausal Patients			
	Test Statistic P-value		Test Statistic	P-value		
$\mathrm{SUV}_{\mathrm{Mean}}$	357	0.735	722	0.004		
SUV <sub>Peak</sub>	277	0.268	618	0.157		
SUV <sub>Max</sub>	295	0.437	614	0.173		
Ki-67	226	0.205	393	0.993		

Table 6. Mann-Whitney U tests identify differences between the log2 fold change in BMI and  $SUV_{Mean}$  in postmenopausal patients, but no other proliferative markers differed in pre- or postmenopausal patients.

285

	Basophils	Eosinophils	Neutrophils	Monocytes	White Blood Cells	Lymphocytes
SUV Mean	0.339	0.619	0.213	0.184	0.803	0.115
SUV <sub>P</sub> eak	0.339	0.803	0.319	0.229	0.431	0.147
SUV Max	0.318	0.803	0.431	0.340	0.481	0.171
Ki-67	0.755 <sup>a</sup>	0.901	0.135	0.584 <sup>a</sup>	0.142 <sup>a</sup>	0.245

**Table 7. Mann-Whitney U and Student's t-tests identify differences between Immune Cells and Proliferative Markers in Premenopausal Patients.** The log2 fold change of each parameter was compared. The comparisons' p-values are shown above. Shapiro-Wilk tests were used to assess the data's normality. Based on these results, normally distributed data were compared using the Student's t-test, and all other analyses used the Mann-Whitney test.

<sup>a</sup> These comparisons use the Student's t-test.

286

	Basophils	Eosinophils	Neutrophils	Monocytes	White Blood Cells	Lymphocytes
SUV Mean	<0.001	<0.001	0.235	<0.001	0.792	<0.001
SUV <sub>P</sub> eak	<0.001	<0.001	0.187	<0.001	0.345	<0.001
SUV Max	<0.001	<0.001	0.124	<0.001	0.244	<0.001
Ki-67	0.010	<0.001	0.091	0.002	0.379	<0.001

**Table 8. Mann-Whitney U tests identify differences between immune cells and proliferative markers in postmenopausal patients.** The log2 fold change of each parameter was compared. The comparisons' p-values are shown above. Significant results are bolded, and marginally significant results are bolded and italicized.

287

### 288 LAT1 Expression and Survival Probability

In the TCGA BRCA gene expression dataset, patients in the high LAT1 expression group experienced lower overall survival than patients in the low expression group until 4000 days after initial treatment. From that point until 6500 days and again from 6600 days until 7500 days, the low LAT1 expression group had a worse overall survival rate (Fig 2A). Similarly, patients with high LAT1 expression had a lower disease-specific survival rate than patients with low LAT1 expression until 4400 days; after that point until the end of the study, patients in the low expression group had a lower disease-specific survival rate (Fig 2B).

296



297

Fig 2. LAT1 expression and prognosis in TCGA BRCA patients. Prognosis in patients from the
 TCGA BRCA gene expression dataset. Patients were separated into high (>= 10.47 FPKM) and low (<</li>
 10.47 FPKM) LAT1 expression groups, and (A) overall survival and (B) disease-specific survival were
 observed up to 8605 days after initial treatment. The median for expression level is slightly different from
 the median stated earlier because patients with indeterminate menopausal status were included in this
 analysis.

304

305 In the "TCGA TARGET GTEx" gene expression dataset, patients in the high LAT1 expression 306 group ( $\geq 10.65$  FPKM) experienced lower survival rates than the low LAT1 expression group 307 (< 10.65 FPKM) until 4000 days after initial treatment. From 4000 days until the end of the 308 study, the low-expression group had a lower survival rate (Fig 3A). In the "Node-negative breast 309 cancer (Desmedt 2007)" gene expression dataset, after the first 500 days, the high LAT1 310 expression group ( $>= 0.1221 \log 2$ ) experienced a lower survival rate than the low LAT1 expression group ( $< 0.1221 \log 2$ ) for the remainder of the study (Fig 3B). In the "ICGC (donor 311 312 centric)" gene expression dataset, the high LAT1 expression group ( $\geq 0.00002400$ ) had lower 313 survival than the low LAT1 expression group (< 0.00002400) for the entire study. The high expression group's survival probability reached 0% near 4000 days (Fig 3C). In the "Breast 314 Cancer (Chin 2006)" gene expression dataset, except from 1.2 to 1.4 years, the high LAT1 315 316 expression group experienced a lower survival rate than the low LAT1 expression group. Units were not given for this study but it most likely used log2 units (Fig 3D). In the "Breast Cancer 317 (Miller 2005)" gene expression dataset, overall survival data were not available so disease-318 specific survival was observed. The high LAT1 expression group ( $>= -0.1707 \log 2$ ) experienced 319 worse survival than the low LAT1 expression group ( $< -0.1707 \log 2$ ) for the entire study (Fig. 320 321 3E). Overall, 2 of the gene expression datasets showed that low LAT1 expression conferred a 322 poorer prognosis in breast cancer patients than high LAT expression, while 4 others showed the 323 opposite. 324



325

- Fig 3. LAT1 expression and prognosis in patients from other datasets. After patients were separated
   into high and low LAT1 expression groups, survival was observed in patients from the (A) "TCGA"
- 328 TARGET GTEx", (B) "Node-negative breast cancer (Desmedt 2007)", (C) "ICGC (donor centric)", (D)
- 329 "Breast Cancer (Chin 2006)", and (E) "Breast Cancer (Miller 2005)" cohorts.
- 330

## 331 Survival probability with high LAT1 expression TCGA BRCA patients by menopausal

#### 332 status

- 333 The impact of menopausal status on survival in patients with high LAT1 expression is shown in
- Fig 4. After 1000 days, postmenopausal patients had the lowest survival rates. Premenopausal
- patients had the highest survival rates among the 3 groups until approximately 2500 days, from

which point peri-menopausal patients had the highest survival until 3600 days (Fig 4); however,

our ability to draw conclusions regarding survival in peri-menopausal patients is limited by therelatively low number of patients in this group.

339



340

Fig 4. High expression and prognosis in TCGA BRCA patients. Prognosis in the high expression
 group (>= 10.46 FPKM) from the TCGA BRCA gene expression dataset. The high expression group was

342 group (>= 10.40 Fr KW) from the FCCA BRCA gene expression dataset. The high expression group was
 343 separated into 3 groups: premenopausal, postmenopausal, and peri-menopausal breast cancer patients.
 344

# 345 Survival probability with low LAT1 expression TCGA BRCA patients by menopausal

346 status

347 The impact of menopausal status on survival in patients with low LAT1 expression is shown in

348 Fig 5. Premenopausal patients had a higher survival rate than postmenopausal patients until 3200

349 days. Postmenopausal patients, after 3200 days and until the end of the available survival data

350 for premenopausal patients at approximately 3800 days, exhibited a higher survival rate

351 compared to premenopausal patients. The few peri-menopausal patients in this study maintained

- a 100% survival probability throughout the duration that they were monitored.
- 353



354

Fig 5. Low expression and prognosis in TCGA BRCA patients. Prognosis in the low expression group
 (< 10.46 FPKM) from the TCGA BRCA gene expression dataset. The low expression group was</li>
 separated into 3 groups: premenopausal, postmenopausal, and peri-menopausal breast cancer patients.

#### 359

#### 360 **Discussion**

Increasing interest in the relationship between systemic metabolism, tumor metabolism, 361 immunometabolism, and cancer outcomes, alongside evolving technologies expanding both the 362 available data and the community's ability to mine it to develop new insights. To that end, in this 363 364 study, we utilized multiple publicly available breast cancer datasets, including "ACRIN-FLT-365 Breast (ACRIN 6688)", TCGA BRCA "Phenotypes", TCGA BRCA "IlluminaHiSeq", "TCGA TARGET GTEx", "Node-negative breast cancer (Desmedt 2007)", "ICGC (donor centric)", 366 367 "Breast Cancer (Chin 2006)", and "Breast Cancer (Miller 2005)", aiming to better understand the 368 intersection between parameters of systemic metabolic health, tumor gene expression, and immune cell infiltration, and outcomes in individuals with breast cancer (Fig 6). 369



371 Fig 6. Summary of factors correlated in this analysis. Figure created with BioRender.com.372

370

373 As opposed to genes or metabolic fluxes involved in glucose [24–31]or lipid metabolism [31– 374 39], there exists a relative paucity of studies exploring the impact of expression of genes regulating amino acid uptake in breast cancer. Therefore, we elected to focus the current study 375 376 on the expression of LAT1, which transports large amino acids including leucine, isoleucine, 377 valine, phenylalanine, methionine, tyrosine, histidine, and tryptophan into the cell, and its 378 relationships with body weight, tumor cell proliferation, and immune infiltration. Prior literature 379 indicates that LAT1 is involved in protein synthesis [40,41] and mTORC1 activity [42,43], and 380 may also modulate the anti-tumor immune response [44–47]. Overexpression of LAT1 has been 381 observed in a plethora of tumor types ranging from lung to endometrial to liver, but fewer studies 382 of the relationship between LAT1 and breast cancer exist [48]. Furthermore, LAT1 has been less 383 frequently associated with a poor long-term clinical prognosis in breast cancer than in other 384 cancers. Our data, too, provide mixed evidence: while some datasets showed that high LAT1 385 expression was worse for prognosis, others showed the opposite. Namely, the BRCA dataset 386 showed that low LAT1 expression conferred worse survival at some points. This is likely 387 because when compared to the high-expression group, a greater proportion of low-expression 388 patients in the BRCA dataset had a positive margin status. Also, a greater percentage of the low-389 expression group had a distant metastasis present. The fact that the low LAT1 expression group tended to have more positive margin status and distant metastases than patients in the high-390 expression group may contribute to the discrepancy between our data on the predictive value of 391 LAT1 versus others, as these have shown to be poor prognostic factors in breast cancer [49,50]. 392 393 Additionally, in the "TCGA TARGET GTEx" dataset, the low-expression group also had lower 394 survival than the high-expression group. Margin status and the presence of distant metastases could also be confounding variables in this dataset, but data were not available to determine that. 395 396 In this way, we show that the relationship between LAT1 expression and survival in breast 397 cancer patients may be more complicated than previously appreciated.

#### 398

399 Past analyses on LAT1 are not stratified by menopausal status, another unique quality of our 400 study. In breast cancer patients with high tumor LAT1 expression, we observed worse survival in 401 postmenopausal individuals as compared to peri- or premenopausal, but interestingly, these 402 relationships were not observed in patients with low LAT1 expression. This discrepancy may 403 reflect the fact that LAT1 has been shown to be estrogen-dependent in endocrine-responsive 404 cells [51,52]. Therefore, it is likely that more of the tumors in the low LAT1 group were triple-405 negative breast cancers, which generally have a poor prognosis independently of menopausal 406 status. We recognize that worse survival is expected over the more than 10-year duration of 407 follow-up in the datasets analyzed in postmenopausal patients, who are older and at greater risk 408 for numerous conditions than their younger counterparts. Thus, the fact that survival differences 409 were not observed in the LAT1 group implies that a regulator of LAT1 expression - such as 410 estrogen - may obscure expected differences in survival. Additionally, we observed a positive 411 correlation (r < 0.5) between BMI and basophil, eosinophil, monocyte, and lymphocyte counts in 412 postmenopausal patients, a finding not seen in premenopausal patients. On the contrary, the 413 opposite was observed in premenopausal patients. Premenopausal patients experience heightened 414 17β-estradiol levels, dampening obesity-induced inflammation, whereas postmenopausal patients (and those with obesity) have higher levels of estrone, stimulating inflammation. The imbalance 415 416 between estrone and 17β-estradiol levels that occurs after menopause results in the release of 417 cytokines and the recruitment of nearby immune cells, which likely explains this correlation only 418 being observed in postmenopausal patients [53][s1].

419

<sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) has been the traditional radiotracer utilized in cancer 420 421 research, and it is still used in the majority of tumor radiotracer analyses. Indeed, the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) is based on the use of <sup>18</sup>F-422 FDG as the radiotracer [54,55]. However, although high <sup>18</sup>F-FDG uptake correlates with poor 423 424 prognosis in numerous tumor types, including breast cancer [56–61], it is not a direct readout of tumor proliferative activity. For this, it is necessary to utilize a tracer such as <sup>18</sup>F-FLT, an analog 425 of thymidine which is phosphorylated by thymidine kinase prior to incorporation into DNA 426 during cell replication. Because our study employs <sup>18</sup>F-FLT imaging as a more direct readout of 427 tumor proliferation rather than <sup>18</sup>F-FDG, we provide an analysis that has previously been 428 429 insufficiently explored. We observe differences in the strength of the correlation between Ki-67 and <sup>18</sup>F-FLT uptake in pre- and postmenopausal patients: in postmenopausal patients, Ki-67 430 significantly positively correlated with <sup>18</sup>F-FLT SUV<sub>Mean</sub>, SUV<sub>Peak</sub>, and SUV<sub>Max</sub>, whereas in 431 premenopausal patients, Ki-67 insignificantly positively correlated with <sup>18</sup>F-FLT. These data are 432 consistent with prior studies in which the correlation between Ki-67 and <sup>18</sup>F-FLT was found to 433 be relatively weak and dependent on clinical variables (pre- or post-treatment timing, hormone 434 receptor status) [62,63]. Surprisingly, BMI barely correlated with either Ki-67 or <sup>18</sup>F-FLT, which 435 may mean that obesity is more involved in the appearance - and potentially recurrence - of 436 437 cancer rather than its progression once a tumor is already established. Further work will be

- 438 required to better understand the nuanced relationships between these clinical variables.
- 439 Additionally, it will be important to understand the relationship between LAT1 expression, <sup>18</sup>F-
- 440 FLT uptake, and clinical variables including BMI and better yet [64] adiposity. In fact, to our
- 441 knowledge, there are no studies correlating LAT1 expression to all 3 types of <sup>18</sup>F-FLT SUVs.
- 442 We recognize that a limitation of our study is that BMI is not the best metric for obesity. In the
- datasets analyzed, there were no clinical data including possible alternatives for BMI like
- 444 visceral adiposity, so we did not have an alternative to relying on BMI. Correlating <sup>18</sup>F-FLT
- 445 uptake to both gene expression and a broad range of anthropometric indices, including visceral
- adiposity, will be of great interest in future studies.
- 447

# 448 Conclusion

- 449 Through our analyses, we show that although the extent to which this occurs is stratified by
- 450 menopausal status, LAT1 expression worsens breast cancer prognosis, bolstering the role of
- 451 amino acid metabolism in tumor energetics, an aspect of the literature that has been
- underexplored. Using various clinical variables, we correlated tumor proliferation, body
- 453 composition, and immune cell populations to identify the complex relationships underlying
- 454 metabolism, immune surveillance, and cancer progression. Future studies should aim to utilize a
- 455 wider variety of immune cell types and metrics for body composition, while further segmenting
- 456 patients based on breast cancer subtype, to gain a more comprehensive understanding of the
- 457 findings we establish here. In addition, we speculate that future studies should target LAT1 or its
- 458 heavy chain partner 4F2hc to inhibit the LAT1-4F2hc complex, interventions which may
- 459 plausibly improve patient outcomes.
- 460

# 461 Acknowledgments

- 462 The authors are grateful for awards from the Lion Heart Foundation and from the Yale Cancer
- 463 Center, which supported this research.
- 464
- 465

#### 466 **References**

- Tangka F, Yabroff R, Jingxuan Z, Mariotto A. The Cost of Cancer | Blogs | CDC. 26 Oct
   2021 [cited 5 Jul 2023]. Available: https://blogs.cdc.gov/cancer/2021/10/26/the-cost-of cancer/
- 470 2. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast
  471 Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians. 2022;72: 524–541.
  472 doi:10.3322/caac.21754
- 473 3. Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends
  474 Biochem Sci. 2016;41: 211–218. doi:10.1016/j.tibs.2015.12.001
- 475 4. Wang D, Wan X. Progress in research on the role of amino acid metabolic reprogramming in tumour therapy: A review. Biomedicine & Pharmacotherapy. 2022;156: 113923.
  477 doi:10.1016/j.biopha.2022.113923
- 478 5. Yang L, Chu Z, Liu M, Zou Q, Li J, Liu Q, et al. Amino acid metabolism in immune cells:
  479 essential regulators of the effector functions, and promising opportunities to enhance cancer
  480 immunotherapy. J Hematol Oncol. 2023;16: 59. doi:10.1186/s13045-023-01453-1
- 481 6. Zhao Y, Wang L, Pan J. The role of L-type amino acid transporter 1 in human tumors.
  482 Intractable Rare Dis Res. 2015;4: 165–169. doi:10.5582/irdr.2015.01024
- 483 7. El Ansari R, Craze ML, Miligy I, Diez-Rodriguez M, Nolan CC, Ellis IO, et al. The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. Breast Cancer Research.
  486 2018;20: 21. doi:10.1186/s13058-018-0946-6
- 487 8. Yan R, Li Y, Müller J, Zhang Y, Singer S, Xia L, et al. Mechanism of substrate transport and
  488 inhibition of the human LAT1-4F2hc amino acid transporter. Cell Discov. 2021;7: 1–8.
  489 doi:10.1038/s41421-021-00247-4
- 490 9. Sanghera B, Wong WL, Sonoda LI, Beynon G, Makris A, Woolf D, et al. FLT PET-CT in
  491 evaluation of treatment response. Indian J Nucl Med. 2014;29: 65–73. doi:10.4103/0972492 3919.130274
- 493 10. Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, et al. A Phase II Study of
  494 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast
  495 Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688. J Nucl Med. 2015;56:
  496 1681–1689. doi:10.2967/jnumed.115.160663
- 497 11. Chang ZF, Huang DY, Hsue NC. Differential phosphorylation of human thymidine kinase in 498 proliferating and M phase-arrested human cells. Journal of Biological Chemistry. 1994;269: 499 21249–21254. doi:10.1016/S0021-9258(17)31956-7

- 12. PECK M, POLLACK HA, FRIESEN A, MUZI M, SHONER SC, SHANKLAND EG, et al.
   Applications of PET imaging with the proliferation marker [18F]-FLT. Q J Nucl Med Mol
   Imaging. 2015;59: 95–104.
- 503 13. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody
  504 reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer.
  505 1983;31: 13–20. doi:10.1002/ijc.2910310104
- 506 14. García-Estévez L, Cortés J, Pérez S, Calvo I, Gallegos I, Moreno-Bueno G. Obesity and
  507 Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal
  508 Status. Frontiers in Oncology. 2021;11. Available:
  509 https://www.frontiersin.org/articles/10.3389/fonc.2021.705911
- 510 15. Kinahan P, Muzi M, Bialecki B, Coombs L. Data from ACRIN-FLT-Breast. The Cancer
   511 Imaging Archive; 2017. doi:10.7937/K9/TCIA.2017.OL20ZMXG
- 512 16. Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, et al. The Cancer Imaging
  513 Archive (TCIA): Maintaining and Operating a Public Information Repository. J Digit
  514 Imaging. 2013;26: 1045–1057. doi:10.1007/s10278-013-9622-7
- 515 17. Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, et al. Visualizing and
  516 interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38: 675–678.
  517 doi:10.1038/s41587-020-0546-8
- 518 18. Liu R, Ospanova S, Perry RJ. The impact of variance in carnitine palmitoyltransferase-1
  519 expression on breast cancer prognosis is stratified by clinical and anthropometric factors.
  520 PLOS ONE. 2023;18: e0281252. doi:10.1371/journal.pone.0281252
- 521 19. Levine EG, Raczynski JM, Carpenter JT. Weight gain with breast cancer adjuvant treatment.
   522 Cancer. 1991;67: 1954–1959. doi:10.1002/1097-0142(19910401)67:7<1954::AID-</li>
   523 CNCR2820670722>3.0.CO;2-Z
- 524 20. Uhelski A-CR, Blackford AL, Sheng JY, Snyder C, Lehman J, Visvanathan K, et al. Factors
  525 associated with weight gain in pre- and post-menopausal women receiving adjuvant
  526 endocrine therapy for breast cancer. J Cancer Surviv. 2023 [cited 5 Jul 2023].
  527 doi:10.1007/s11764-023-01408-y
- 528 21. Walker J, Joy AA, Vos LJ, Stenson TH, Mackey JR, Jovel J, et al. Chemotherapy-induced
  529 weight gain in early-stage breast cancer: a prospective matched cohort study reveals
  530 associations with inflammation and gut dysbiosis. BMC Medicine. 2023;21: 178.
  531 doi:10.1186/s12916-023-02751-8
- 532 22. Ee C, Cave A, Vaddiparthi V, Naidoo D, Boyages J. Factors associated with weight gain
  533 after breast cancer: Results from a community-based survey of Australian women. The
  534 Breast. 2023;69: 491–498. doi:10.1016/j.breast.2023.01.012

535 23. Könik A, O'Donoghue JA, Wahl RL, Graham MM, Van den Abbeele AD. Theranostics: The
536 Role of Quantitative Nuclear Medicine Imaging. Seminars in Radiation Oncology. 2021;31:
537 28–36. doi:10.1016/j.semradonc.2020.07.003

- 538 24. Grinde MT, Moestue SA, Borgan E, Risa Ø, Engebraaten O, Gribbestad IS. 13C High539 resolution-magic angle spinning MRS reveals differences in glucose metabolism between
  540 two breast cancer xenograft models with different gene expression patterns. NMR in
  541 Biomedicine. 2011;24: 1243–1252. doi:10.1002/nbm.1683
- 542 25. Bawab AQA, Zihlif M, Jarrar Y, Sharab A. Continuous Hypoxia and Glucose Metabolism:
  543 The Effects on Gene Expression in Mcf7 Breast Cancer Cell Line. Endocrine, Metabolic &
  544 Immune Disorders Drug Targets. 21: 511–519.
- 545 26. Cheng X, Jia X, Wang C, Zhou S, Chen J, Chen L, et al. Hyperglycemia induces PFKFB3
  546 overexpression and promotes malignant phenotype of breast cancer through RAS/MAPK
  547 activation. World Journal of Surgical Oncology. 2023;21: 112. doi:10.1186/s12957-023548 02990-2
- 549 27. Jekabsons MB, Merrell M, Skubiz AG, Thornton N, Milasta S, Green D, et al. Breast cancer
  550 cells that preferentially metastasize to lung or bone are more glycolytic, synthesize serine at
  551 greater rates, and consume less ATP and NADPH than parent MDA-MB-231 cells. Cancer
  552 & Metabolism. 2023;11: 4. doi:10.1186/s40170-023-00303-5
- 553 28. Tucker JD, Doddapaneni R, Lu PJ, Lu QL. Ribitol alters multiple metabolic pathways of
  554 central carbon metabolism with enhanced glycolysis: A metabolomics and transcriptomics
  555 profiling of breast cancer. PLOS ONE. 2022;17: e0278711.
  556 doi:10.1371/journal.pone.0278711
- 29. Zhu P, Liu G, Wang X, Lu J, Zhou Y, Chen S, et al. Transcription factor c-Jun modulates
  GLUT1 in glycolysis and breast cancer metastasis. BMC Cancer. 2022;22: 1283.
  doi:10.1186/s12885-022-10393-x
- 30. Ambrosio MR, Mosca G, Migliaccio T, Liguoro D, Nele G, Schonauer F, et al. Glucose
  Enhances Pro-Tumorigenic Functions of Mammary Adipose-Derived Mesenchymal
  Stromal/Stem Cells on Breast Cancer Cell Lines. Cancers (Basel). 2022;14: 5421.
  doi:10.3390/cancers14215421
- 564 31. Lee R, Lee H-B, Paeng JC, Choi H, Whi W, Han W, et al. Association of androgen receptor
  565 expression with glucose metabolic features in triple-negative breast cancer. PLOS ONE.
  566 2022;17: e0275279. doi:10.1371/journal.pone.0275279
- 567 32. Monaco ME. ACSL4: biomarker, mediator and target in quadruple negative breast cancer.
  568 Oncotarget. 2023;14: 563–575. doi:10.18632/oncotarget.28453

33. Tang L, Lei X, Hu H, Li Z, Zhu H, Zhan W, et al. Investigation of fatty acid metabolismrelated genes in breast cancer: Implications for Immunotherapy and clinical significance.
Translational Oncology. 2023;34: 101700. doi:10.1016/j.tranon.2023.101700

- 34. Miyashita M, Bell JSK, Wenric S, Karaesmen E, Rhead B, Kase M, et al. Molecular
  profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals
  actionable tumor biology differences between European ancestry and African ancestry
  patient populations. Breast Cancer Research. 2023;25: 58. doi:10.1186/s13058-023-01627-2
- 35. Qian L, Liu Y-F, Lu S-M, Yang J-J, Miao H-J, He X, et al. Construction of a fatty acid
  metabolism-related gene signature for predicting prognosis and immune response in breast
  cancer. Front Genet. 2023;14: 1002157. doi:10.3389/fgene.2023.1002157
- 36. Qian Z, Chen L, Liu J, Jiang Y, Zhang Y. The emerging role of PPAR-alpha in breast cancer. Biomedicine & Pharmacotherapy. 2023;161: 114420.
  doi:10.1016/j.biopha.2023.114420
- 37. Yousuf U, Sofi S, Makhdoomi A, Mir MA. Identification and analysis of dysregulated fatty
  acid metabolism genes in breast cancer subtypes. Med Oncol. 2022;39: 256.
  doi:10.1007/s12032-022-01861-2
- 38. Chang X, Xing P. Identification of a novel lipid metabolism-related gene signature within
  the tumour immune microenvironment for breast cancer. Lipids in Health and Disease.
  2022;21: 43. doi:10.1186/s12944-022-01651-9
- 39. Pham D-V, Park P-H. Adiponectin triggers breast cancer cell death via fatty acid metabolic
  reprogramming. Journal of Experimental & Clinical Cancer Research. 2022;41: 9.
  doi:10.1186/s13046-021-02223-y
- 40. Collao N, Akohene-Mensah P, Nallabelli J, Binet ER, Askarian A, Lloyd J, et al. The role of
  L-type amino acid transporter 1 (Slc7a5) during in vitro myogenesis. American Journal of
  Physiology-Cell Physiology. 2022;323: C595–C605. doi:10.1152/ajpcell.00162.2021
- 41. Nishikubo K, Ohgaki R, Okanishi H, Okuda S, Xu M, Endou H, et al. Pharmacologic
  inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and
  downregulates global translation in cancer cells. Journal of Cellular and Molecular Medicine.
  2022;26: 5246–5256. doi:10.1111/jcmm.17553
- 42. Chiduza GN, Johnson RM, Wright GSA, Antonyuk SV, Muench SP, Hasnain SS. LAT1
  (SLC7A5) and CD98hc (SLC3A2) complex dynamics revealed by single-particle cryo-EM.
  Acta Crystallogr D Struct Biol. 2019;75: 660–669. doi:10.1107/S2059798319009094
- 43. Li Y, Wang W, Wu X, Ling S, Ma Y, Huang P. SLC7A5 serves as a prognostic factor of
  breast cancer and promotes cell proliferation through activating AKT/mTORC1 signaling
  pathway. Ann Transl Med. 2021;9: 892. doi:10.21037/atm-21-2247
- 44. Solvay M, Holfelder P, Klaessens S, Pilotte L, Stroobant V, Lamy J, et al. Tryptophan
  depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes. J
  Immunother Cancer. 2023;11: e006728. doi:10.1136/jitc-2023-006728

- 45. Tian X, Liu X, Ding J, Wang F, Wang K, Liu J, et al. An anti-CD98 antibody displaying pHdependent Fc-mediated tumour-specific activity against multiple cancers in CD98humanized mice. Nat Biomed Eng. 2023;7: 8–23. doi:10.1038/s41551-022-00956-5
- 46. Liu Y-H, Li Y-L, Shen H-T, Chien P-J, Sheu G-T, Wang B-Y, et al. L-Type Amino Acid
  Transporter 1 Regulates Cancer Stemness and the Expression of Programmed Cell Death 1
  Ligand 1 in Lung Cancer Cells. Int J Mol Sci. 2021;22: 10955. doi:10.3390/ijms222010955
- 47. Kuriyama K, Higuchi T, Yokobori T, Saito H, Yoshida T, Hara K, et al. Uptake of positron
  emission tomography tracers reflects the tumor immune status in esophageal squamous cell
  carcinoma. Cancer Sci. 2020;111: 1969–1978. doi:10.1111/cas.14421
- 48. Häfliger P, Charles R-P. The L-Type Amino Acid Transporter LAT1—An Emerging Target
  in Cancer. Int J Mol Sci. 2019;20: 2428. doi:10.3390/ijms20102428
- 49. Xiao W, Zheng S, Yang A, Zhang X, Zou Y, Tang H, et al. Breast cancer subtypes and the
  risk of distant metastasis at initial diagnosis: a population-based study. Cancer Manag Res.
  2018;10: 5329–5338. doi:10.2147/CMAR.S176763
- 50. Bundred JR, Michael S, Stuart B, Cutress RI, Beckmann K, Holleczek B, et al. Margin status
  and survival outcomes after breast cancer conservation surgery: prospectively registered
  systematic review and meta-analysis. BMJ. 2022;378: e070346. doi:10.1136/bmj-2022070346
- 51. Sevigny CM, Sengupta S, Luo Z, Liu X, Hu R, Zhang Z, et al. SLCs contribute to endocrine
  resistance in breast cancer: role of SLC7A5 (LAT1). bioRxiv; 2019. p. 555342.
  doi:10.1101/555342
- 52. Shennan DB, Thomson J, Gow IF, Travers MT, Barber MC. l-Leucine transport in human
  breast cancer cells (MCF-7 and MDA-MB-231): kinetics, regulation by estrogen and
  molecular identity of the transporter. Biochimica et Biophysica Acta (BBA) Biomembranes. 2004;1664: 206–216. doi:10.1016/j.bbamem.2004.05.008
- 633 53. Qureshi R, Picon-Ruiz M, Aurrekoetxea-Rodriguez I, Paiva VN de, D'Amico M, Yoon H, et
  634 al. The Major Pre- and Postmenopausal Estrogens Play Opposing Roles in Obesity-Driven
  635 Mammary Inflammation and Breast Cancer Development. Cell Metabolism. 2020;31: 1154636 1172.e9. doi:10.1016/j.cmet.2020.05.008
- 54. Sato M, Harada-Shoji N, Toyohara T, Soga T, Itoh M, Miyashita M, et al. L-type amino acid
  transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino
  acid metabolism. Sci Rep. 2021;11: 589. doi:10.1038/s41598-020-80668-5
- 55. Kitajima K, Nakatani K, Yamaguchi K, Nakajo M, Tani A, Ishibashi M, et al. Response to
  neoadjuvant chemotherapy for breast cancer judged by PERCIST multicenter study in
  Japan. Eur J Nucl Med Mol Imaging. 2018;45: 1661–1671. doi:10.1007/s00259-018-4008-1
- 643 56. Cremoux P de, Biard L, Poirot B, Bertheau P, Teixeira L, Lehmann-Che J, et al. 18 FDG 644 PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and

- outcome in HER2-negative advanced luminal breast cancers patients. Oncotarget. 2018;9:
  16343–16353. doi:10.18632/oncotarget.24674
- 57. Groheux D, Martineau A, Teixeira L, Espié M, de Cremoux P, Bertheau P, et al. 18FDGPET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of
  clinicopathological parameters and PET image-derived indices including tumor texture
  analysis. Breast Cancer Research. 2017;19: 3. doi:10.1186/s13058-016-0793-2
- 58. Humbert O, Riedinger J-M, Charon-Barra C, Berriolo-Riedinger A, Desmoulins I, Lorgis V,
  et al. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of
  Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Clin Cancer Res.
  2015;21: 5460–5468. doi:10.1158/1078-0432.CCR-15-0384
- 655 59. Groheux D, Sanna A, Majdoub M, Cremoux P de, Giacchetti S, Teixeira L, et al. Baseline
  656 Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy
  657 Are Prognostic of Outcome in ER+/HER2– Breast Cancer. Journal of Nuclear Medicine.
  658 2015;56: 824–831. doi:10.2967/jnumed.115.154138
- 659 60. Cochet A, David S, Moodie K, Drummond E, Dutu G, MacManus M, et al. The utility of 18
  660 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification.
  661 Cancer Imaging. 2014;14: 13. doi:10.1186/1470-7330-14-13
- 662 61. Jacobs MA, Ouwerkerk R, Wolff AC, Gabrielson E, Warzecha H, Jeter S, et al. Monitoring
  663 of neoadjuvant chemotherapy using multiparametric, <sup>23</sup>Na sodium MR, and multimodality
  664 (PET/CT/MRI) imaging in locally advanced breast cancer. Breast Cancer Res Treat.
  665 2011;128: 119–126. doi:10.1007/s10549-011-1442-1
- 666 62. Romine PE, Peterson LM, Kurland BF, Byrd DW, Novakova-Jiresova A, Muzi M, et al.
  667 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early
  668 response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a
  669 window-of-opportunity study. Breast Cancer Research. 2021;23: 88. doi:10.1186/s13058670 021-01464-1
- 63. Su T-P, Huang J-S, Chang P-H, Lui K-W, Hsieh JC-H, Ng S-H, et al. Prospective
  comparison of early interim 18F-FDG-PET with 18F-FLT-PET for predicting treatment
  response and survival in metastatic breast cancer. BMC Cancer. 2021;21: 908.
  doi:10.1186/s12885-021-08649-z
- 675 64. Leitner BP, Givechian KB, Ospanova S, Beisenbayeva A, Politi K, Perry RJ. Multimodal
  676 analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma
  677 and adenocarcinoma. npj Precis Onc. 2022;6: 1–10. doi:10.1038/s41698-021-00248-2

678